Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03334747
Recruitment Status : Completed
First Posted : November 7, 2017
Results First Posted : September 25, 2020
Last Update Posted : September 25, 2020
Sponsor:
Collaborator:
Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in sequential cohorts with increasing doses.This study aims to determine the maximum safe dose of the investigational drug KAE609 in malaria patients.

Condition or disease Intervention/treatment Phase
Malaria Drug: KAE609 Drug: Coartem Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 188 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients were randomized to KAE609 and Coartem in parallel treatment arms. Increasing doses of KAE609 (single dose and multiple dose) were evaluated in dose escalated manner in sequential cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria.
Actual Study Start Date : November 16, 2017
Actual Primary Completion Date : November 23, 2019
Actual Study Completion Date : November 23, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Treatment arm 1: KAE609 10 mg Single Dose (SD)
KAE609 10 mg once daily (QD) for 1 day
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 2:KAE609 25 mg SD
KAE609 25 mg once daily (QD) for 1 day
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 3:KAE609 10 mg 3 Days
KAE609 10 mg (QD) for 3 days
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 4:KAE609 50 mg SD
KAE609 50 mg once daily (QD) for 1 day
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 5:KAE609 25 mg 3 Days
KAE609 25 mg once daily (QD) for 3 days
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 6:KAE609 75 mg SD
KAE609 75 mg once daily (QD) for 1 day
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 7:KAE609 50 mg 3 Days
KAE609 50 mg once daily (QD) for 3 days
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Experimental: Treatment arm 8: KAE609 150 mg SD
KAE609 150 mg once daily (QD) for 1 day
Drug: KAE609
Exploration of different doses of KAE609 to establish safety profile.
Other Name: Cipargamin

Active Comparator: Treatment arm 9: Coartem Control
Coartem® control
Drug: Coartem
Control Arm
Other Name: Artemether Lumefantrine




Primary Outcome Measures :
  1. Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) [ Time Frame: Day 29 ]
    The occurrence of at least 2 CTCAE grades increase from baseline in ALT or AST during the 4 weeks study period was evaluated to characterize hepatic safety aspects of single and multiple ascending doses of KAE609 in adult malaria subjects for treatment of uncomplicated malaria caused by plasmodium falciparum. If 2 patients in a 10 patient cohort (Cohorts 1 and 2) or 3 patients in a 20 patient cohort (Cohorts 3, 4 and 5) had at least 2 CTCAE grades increase from Baseline in ALT or AST, recruitment was suspended and a review of liver safety (and any other relevant data) by safety review committee was initiated. Any further progression of the study was based on the decision by the safety review committee.


Secondary Outcome Measures :
  1. Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29 [ Time Frame: Day 15, Day 29 ]
    PCR-corrected and PCR-uncorrected were evaluated at Days 15 and 29 (i.e., 14 and 28 days post-dose). The presence of parasitaemia after 7 days due to reinfection was considered as PCR-corrected ACPR. Missing blood smear data at Day 15 visit and thereafter were not considered as responder for the visit unless there was a later blood smear test indicating no parasitaemia.

  2. Parasite Clearance Time (PCT) [ Time Frame: Day 29 ]
    Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours. In case a patient received rescue medication before (parasite) clearance, the time to event was censored at the first use of rescue medication.

  3. Fever Clearance Time (FCT) [ Time Frame: Day 29 ]
    Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours. In case a patient received rescue medication before (fever) clearance, the time to event was censored at the first use of rescue medication.

  4. Time to Recrudescence and Reinfection at Study Day 29 [ Time Frame: Day 29 ]
    Time to recrudescence is calculated from the date of first study medication to the date of first event. Participants without recrudescence/reinfection after Day 7 are censored at the time of treatment failure or at the time of last parasite assessment if no treatment failure occured.

  5. Maximum Peak Observed Concentration (Cmax) [ Time Frame: Day 1, Day 3 ]
    Maximum Peak Observed Concentration (Cmax)

  6. Tmax [ Time Frame: Day 1, Day 3 ]
    Tmax

  7. AUC0-24 [ Time Frame: Day 1, Day 3 ]
    AUC0-24

  8. Half-life (T^1/2) [ Time Frame: Upto day 15 post dose ]
    Half-life (T^1/2)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

KEY Inclusion Criteria:

  1. Male and female patients ≥ 18 years with a body weight ≥ 45 kg.
  2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained thick film.
  3. P. falciparum parasitaemia of 500 to 50 000 parasites/µL.
  4. Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours.
  5. Written informed consent must be obtained before any study assessment is performed. If the patient is unable to write, then a witnessed consent according to local ethical standards is permitted.

KEY Exclusion Criteria:

  1. Mixed Plasmodium infections.
  2. Signs and symptoms of severe malaria according to World Health Organization (WHO) 2016 criteria (WHO 2016).
  3. Known liver abnormalities, liver cirrhosis (compensated or decompensated), known active or history of hepatitis B or C (testing not required), known gallbladder or bile duct disease, acute or chronic pancreatitis.
  4. Clinical or laboratory evidence of any of the following:
  5. AST/ALT > 1.5 x the upper limit of normal range (ULN), regardless of the level of total bilirubin
  6. AST/ALT > 1.0 and ≤ 1.5 x ULN and total bilirubin is > ULN
  7. Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
  8. History of photodermatitis/increased sensitivity to sun.
  9. Pregnant or nursing (lactating) women.
  10. Known disturbances of electrolyte balance, e.g. hypokalemia, hypocalcemia or hypomagnesemia.
  11. Moderate to severe anemia (Hemoglobin level <8 g/dL).

Other protocol-defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03334747


Locations
Layout table for location information
Gabon
Novartis Investigative Site
Lambarene, Gabon
Ghana
Novartis Investigative Site
Kintampo, Ghana
Novartis Investigative Site
Navrango, Ghana
Mali
Novartis Investigative Site
Bamako, Mali
Novartis Investigative Site
Sotuba, Mali
Rwanda
Novartis Investigative Site
Kigali, Rwanda
Uganda
Novartis Investigative Site
Bushenyi, Uganda
Novartis Investigative Site
Kampala, Uganda
Novartis Investigative Site
Tororo, Uganda
Sponsors and Collaborators
Novartis Pharmaceuticals
Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Novartis ( Novartis Pharmaceuticals ):
Study Protocol  [PDF] May 27, 2019
Statistical Analysis Plan  [PDF] April 7, 2020

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03334747    
Other Study ID Numbers: CKAE609A2202
207813/Z/17/Z ( Other Grant/Funding Number: Wellcome Trust )
First Posted: November 7, 2017    Key Record Dates
Results First Posted: September 25, 2020
Last Update Posted: September 25, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
uncomplicated Plasmodium falciparum Malaria.
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Lumefantrine
Artemether
Artemether, Lumefantrine Drug Combination
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents